Evaluating Iruplinalkib for ALK-Positive Lung Cancer
Real-World Study of Iruplinalkib in the Treatment of ALK-Positive Non-Small Cell Lung Cancer
This study is testing if Iruplinalkib is safe and effective for people in China with ALK-positive non-small cell lung cancer who have already received this treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Shandong Cancer Hospital and Institute Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Jinan, Shandong) |
| Trial ID | NCT05991895 on ClinicalTrials.gov |
What this trial studies
This national multicenter investigation assesses the effectiveness and safety of Iruplinalkib in treating patients with ALK-positive non-small cell lung cancer (NSCLC) in China. The study will enroll patients who have previously received Iruplinalkib, collecting data on their demographics, medical history, treatment regimens, clinical outcomes, and any adverse events. As an observational study, it will rely on routine clinical practices and patients' medical records for data collection.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with ALK-positive non-small cell lung cancer who have previously been treated with Iruplinalkib.
Not a fit: Patients who are pregnant, lactating, or have certain lung conditions requiring ongoing medical intervention may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the real-world effectiveness of Iruplinalkib, potentially improving treatment strategies for ALK-positive NSCLC patients.
How similar studies have performed: While this study focuses on real-world data, similar studies evaluating targeted therapies in lung cancer have shown promising results, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients willingly contribute their clinical data for this study * Patients with ALK-positive non-small cell lung cancer * Age ≥ 18 years * Patients who have undergone treatment with Iruplinalkib. Exclusion Criteria: * Known pregnant or lactating females * Patients with interstitial lung diseases, drug-related pneumonitis, or radiation pneumonitis require ongoing medical intervention.
Where this trial is running
Jinan, Shandong
- Shandong Cancer Hospital and Institute — Jinan, Shandong, China (Recruiting)
Study contacts
- Principal investigator: JinMing Yu, PhD — Shandong Cancer Hospital and Institute
- Study coordinator: Jinming Yu, PhD
- Email: jn7984729@public.jn.sd.cn
- Phone: 8613806406293
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.